TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
AVEX

AEVEX Corp.

Industrials · Aerospace & Defense

18.90$ -5.1% vs. previous close Closing price · As of: Aug 19, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of AEVEX Corp. (AVEX). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — AVEX
Segment Q2 2025 Q2 2026
Tactical Systems $72.1M 71.3% $174.2M 86.3%
Global Solutions $29.0M 28.7% $27.6M 13.7%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by region

Revenue by region — AVEX
Segment Q2 2025 Q2 2026
United States $96.5M 95.4% $198.6M 98.4%
Other foreign countries $4.7M 4.6% $3.2M 1.6%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by product line

Revenue by product line — AVEX
Segment Q2 2025 Q2 2026
Products $70.8M 70.0% $168.7M 83.6%
Services $30.3M 30.0% $33.1M 16.4%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Remaining performance obligations

Remaining performance obligations are the part of the business already sold but not yet delivered and therefore not yet booked as revenue. In subscription and project businesses it points the way earlier than revenue does.

Remaining performance obligations — AVEX
As of Remaining performance obligations
Q2 2026 $259.8M

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 19, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?